Huma Therapeutics closes $80M in a Series D funding round led by AstraZeneca, Hitachi Ventures, and Bayer to launch a 'Shopify-like' AI digital health platform

Jul 16, 2024•over 1 year ago

Amount Raised

$80 Million

Round Type

series d

LondonMedicalArtificial IntelligenceBiotechnologyHealth Care

Investors

Leaps By BayerHv Fund By Hitachi VenturesHat Technology Fund 4Astra Zeneca

Description

Huma Therapeutics has closed a $80M Series D funding round, bringing the total funding raised to $300 million. The round saw participation from AstraZeneca, Hat Technology Fund 4, HV Fund by Hitachi Ventures, Leaps by Bayer, and others. In addition, the company has launched Huma Cloud Platform, a GenAI-powered 'Shopify-like' experience for the digital health ecosystem.

Company Information

Company

Huma Therapeutics

Location

London, England, United Kingdom

About

Huma Therapeutics is a healthcare AI company focused on accelerating the adoption of digital solutions in care and research. Their technology powers multi-channel patient engagement at population-wide scale for healthcare systems, remote patient monitoring (RPM) at scale, companion apps to support patients through treatment and drug therapies, and digital clinical trials to accelerate medical research.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends